193 related articles for article (PubMed ID: 30225758)
1. Pharmacokinetic Modeling of Targeted Ultrasound Contrast Agents for Quantitative Assessment of Anti-Angiogenic Therapy: a Longitudinal Case-Control Study in Colon Cancer.
Turco S; El Kaffas A; Zhou J; Lutz AM; Wijkstra H; Willmann JK; Mischi M
Mol Imaging Biol; 2019 Aug; 21(4):633-643. PubMed ID: 30225758
[TBL] [Abstract][Full Text] [Related]
2. Three-dimensional ultrasound molecular imaging of angiogenesis in colon cancer using a clinical matrix array ultrasound transducer.
Wang H; Kaneko OF; Tian L; Hristov D; Willmann JK
Invest Radiol; 2015 May; 50(5):322-9. PubMed ID: 25575176
[TBL] [Abstract][Full Text] [Related]
3. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
[TBL] [Abstract][Full Text] [Related]
4. VEGFR2-Targeted Three-Dimensional Ultrasound Imaging Can Predict Responses to Antiangiogenic Therapy in Preclinical Models of Colon Cancer.
Zhou J; Wang H; Zhang H; Lutz AM; Tian L; Hristov D; Willmann JK
Cancer Res; 2016 Jul; 76(14):4081-9. PubMed ID: 27206846
[TBL] [Abstract][Full Text] [Related]
5. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
[TBL] [Abstract][Full Text] [Related]
6. Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging.
Zhou J; Zhang H; Wang H; Lutz AM; El Kaffas A; Tian L; Hristov D; Willmann JK
Angiogenesis; 2017 Nov; 20(4):547-555. PubMed ID: 28721500
[TBL] [Abstract][Full Text] [Related]
7. Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
Turco S; Tardy I; Frinking P; Wijkstra H; Mischi M
Phys Med Biol; 2017 Mar; 62(6):2449-2464. PubMed ID: 28240217
[TBL] [Abstract][Full Text] [Related]
8. Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
Baetke SC; Rix A; Tranquart F; Schneider R; Lammers T; Kiessling F; Lederle W
Radiology; 2016 Feb; 278(2):430-40. PubMed ID: 26313618
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects.
Palmowski M; Huppert J; Ladewig G; Hauff P; Reinhardt M; Mueller MM; Woenne EC; Jenne JW; Maurer M; Kauffmann GW; Semmler W; Kiessling F
Mol Cancer Ther; 2008 Jan; 7(1):101-9. PubMed ID: 18202013
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).
Pysz MA; Foygel K; Rosenberg J; Gambhir SS; Schneider M; Willmann JK
Radiology; 2010 Aug; 256(2):519-27. PubMed ID: 20515975
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model.
Helbert A; Von Wronski M; Colevret D; Botteron C; Padilla F; Bettinger T; Tardy I; Hyvelin JM
Invest Radiol; 2020 Oct; 55(10):657-665. PubMed ID: 32229739
[TBL] [Abstract][Full Text] [Related]
12. Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy.
Sorace AG; Saini R; Mahoney M; Hoyt K
J Ultrasound Med; 2012 Oct; 31(10):1543-50. PubMed ID: 23011617
[TBL] [Abstract][Full Text] [Related]
13. BR55: a lipopeptide-based VEGFR2-targeted ultrasound contrast agent for molecular imaging of angiogenesis.
Pochon S; Tardy I; Bussat P; Bettinger T; Brochot J; von Wronski M; Passantino L; Schneider M
Invest Radiol; 2010 Feb; 45(2):89-95. PubMed ID: 20027118
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional Dynamic Contrast-enhanced US Imaging for Early Antiangiogenic Treatment Assessment in a Mouse Colon Cancer Model.
Wang H; Hristov D; Qin J; Tian L; Willmann JK
Radiology; 2015 Nov; 277(2):424-34. PubMed ID: 26020439
[TBL] [Abstract][Full Text] [Related]
15. [Value of ultrasound-targeted vascular endothelial growth factor receptor-2 in non-invasive monitoring of anti-angiogenic response in nude mice with subcutaneous xenograft model].
Wang L; Lu YH; Wang TY
Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):856-860. PubMed ID: 33113627
[No Abstract] [Full Text] [Related]
16. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent.
Abou-Elkacem L; Wilson KE; Johnson SM; Chowdhury SM; Bachawal S; Hackel BJ; Tian L; Willmann JK
Theranostics; 2016; 6(11):1740-52. PubMed ID: 27570547
[TBL] [Abstract][Full Text] [Related]
18. Assessment and monitoring tumor vascularity with contrast-enhanced ultrasound maximum intensity persistence imaging.
Pysz MA; Foygel K; Panje CM; Needles A; Tian L; Willmann JK
Invest Radiol; 2011 Mar; 46(3):187-95. PubMed ID: 21150790
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of high frequency ultrasound methods and contrast agents for characterising tumor response to anti-angiogenic treatment.
Rix A; Lederle W; Siepmann M; Fokong S; Behrendt FF; Bzyl J; Grouls C; Kiessling F; Palmowski M
Eur J Radiol; 2012 Oct; 81(10):2710-6. PubMed ID: 22093958
[TBL] [Abstract][Full Text] [Related]
20. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
Willmann JK; Paulmurugan R; Chen K; Gheysens O; Rodriguez-Porcel M; Lutz AM; Chen IY; Chen X; Gambhir SS
Radiology; 2008 Feb; 246(2):508-18. PubMed ID: 18180339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
